Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multi-arm study of tislelizumab combined with investigational agents with or without chemotherapy in previously untreated advanced NSCLC
CTR20230892Phase 2Active
- Sponsor
- BeOne Medicines
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, gimistotug, alcestobart, BGB-15025 in non-small cell lung cancer (NSCLC), sponsored by BeOne Medicines. Started Apr 2023; status: active.
02
Drugs
tislelizumabgimistotugalcestobartBGB-15025
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20230892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230892.